Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HNF4A | P41235 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4097562 | 0.87 | HNF4A (0.32) | FFAR1HNF4A | |
| SCHEMBL4102964 | 0.74 | TSHR (0.43) | ALDH1A1TDP1HSD17B10 | |
| SCHEMBL4097557 | 0.72 | CCR2 (0.47) | FFAR1ALOX5 | |
| SCHEMBL4091277 | 0.70 | CCR2 (0.47) | — | |
| SCHEMBL4091073 | 0.70 | CCR2 (0.38) | FFAR1 | |
| SCHEMBL4096233 | 0.68 | CCR2 (0.57) | — | |
| SCHEMBL4102959 | 0.62 | MAPT (0.58) | ALOX5ALDH1A1TDP1 | |
| SCHEMBL10300111 | 0.60 | APP (0.48) | ALDH1A1HSD17B10 | |
| SCHEMBL4407685 | 0.58 | RAB9A (0.44) | FFAR1ALDH1A1HNF4A | |
| SCHEMBL29270348 | 0.57 | APP (0.42) | FFAR1ALDH1A1TDP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | NPY5R, TH, PTGES | FFAR1 3026/4885ALOX5 188/4885ALDH1A1 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.